國藥股份(600511.SH):子公司與上海統御擬清算註銷北京統御
格隆匯 10 月 21日丨國藥股份(600511.SH)公佈,公司的全資子公司國藥控股北京康辰生物醫藥有限公司(“國控康辰”)與上海統御信息科技有限公司(“上海統御”)擬清算註銷北京統御信息科技有限公司(“北京統御”)。
公司的全資子公司國控康辰持有北京統御80%的股權,上海統御持有北京統御20%的股權,公司的控股股東國藥控股股份有限公司持有上海統御100%的股權,因此上海統御為公司的關聯法人,故此次清算註銷事項構成關聯交易。
為優化資源配置,提高經營效率,保護公司及股東利益,擬對北京統御進行清算註銷。此次清算註銷對公司業務發展和財務狀況不會產生重大影響,不會損害公司及股東特別是中小投資者的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.